Abstract
Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field of research. This article reviews the current preclinical and clinical status, including a discussion of the molecular basis for the activity of the parent drug cisplatin and platinum drugs of the second and third generation, in particular their interaction with DNA. Further emphasis is laid on the development of third generation platinum drugs with activity in cisplatin-resistant tumours, particularly on chelates containing 1,2-diaminocyclohexane (DACH) and on the promising and more recently evolving field of non-classic (trans- and multinuclear) platinum complexes. The development of oral platinum drugs and drug targeting strategies using liposomes, polymers or low-molecular-weight carriers in order to improve the therapeutic index of platinum chemotherapy are also covered.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087–3090
Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y (1992) Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 31:187–192
Akiyama M, Horiguchi-Yamada J, Saito S, Hoshi Y, Yamada O, Mizoguchi H, Yamada H (1999) Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur J Cancer 35:309–315
Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, Gamelin E (2000) Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28:1379–1384
Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, Choy H (1999) Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys 44:399–405
Amorino GP, Mohr PJ, Hercules SK, Pyo H, Choy H (2000) Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 46:423–426
Andrews PA (2000) Cisplatin accumulation. In: Kelland LR, Farrell N (eds) Platinum-based drugs in cancer therapy. Humana, Totowa, pp 89–113
Andrews PA, Jones JA, Varki NM, Howell SB (1990) Rapid emergence of acquired cis-dichlorodiammineplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2:93–100
Angerer EV (1993) Platinum complexes with specific activity against hormone-dependent tumors. In: Keppler BK (ed) Metal complexes in cancer chemotherapy. VCH, Weinheim, pp 73–83
Armand JP, Boige V, Raymond E, Fizazi K, Faivre S, Ducreux M (2000) Oxaliplatin in colorectal cancer: an overview. Semin Oncol 27, Suppl 10:96–104
Ayrapetian LG (1996) New analog of platinum—cycloplatam—treatment of breast cancer. Proc Int Congress on Anti-Cancer Chemother 6:403
Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV (1989) Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 86:6313–6317
Bancroft DP, Lepre CA, Lippard SJ (1990) 195Pt NMR kinetic and mechanistic studies of cis-and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc 112:6860–6871
Barnham KJ, Berners-Price SJ, Frenkiel TA, Frey U, Sadler PJ (1995a) Platination pathways for reactions of cisplatin with GG single-stranded and double-stranded decanucleotides. Angew Chem Int Ed Engl 34:1874–1877
Barnham KJ, Djuran MI, Murdoch P del S, Ranford JD, Sadler PJ (1995b) l-Methionine increases the rate of reaction of 5′-guanosine monophosphate with the anticancer drug cisplatin: mixed-ligand adducts and reversible methionine binding. J Chem Soc Dalton Trans 1995:3721–3726
Barnham KJ, Djuran MI, Murdoch P del S, Ranford JD, Sadler PJ (1996) Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg Chem 35:1065–1072
Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353–2362
Bedford P, Fichtinger-Shepman AMJ, Shellard SA, Walker MC, Masters JRW, Hill BT (1988) Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48:3019–3024
Bednarski PJ, Gust R, Spruss T, Knebel N, Otto A, Farbel M, Koop R, Holler E, Angerer EV, Schönenberger H (1990) Platinum compounds with estrogen receptor affinity. Cancer Treat Rev 17:221–231
Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414–418
Beketic-Oreskovic L, Osmak M (1995) Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells. Cancer Chemother Pharmacol 35:327–333
Belguise-Valladier P, Maki H, Sekiguchi M, Fuchs RP (1994) Effect of single DNA lesions on in vitro replication with DNA polymerase III holoenzyme. Comparison with other polymerases. J Mol Biol 236:151–164
Berners-Price SJ, Appleton TG (2000) The chemistry of cisplatin in aqueous solution. In: Kelland LR, Farrell N (eds) Platinum-based drugs in cancer therapy. Humana, Totowa pp 335
Bérubé G, Wheeler P, Ford CHJ, Gallant M, Tsaltsas Z (1993) Synthesis and preliminary in vitro biological activity of non-steroidal cytotoxic estrogens designed for the treatment of breast cancer. Can J Chem 71:1327–1333
Bérubé G, He Y, Groleau S, Séné A, Thérien HM, Caron M (1997) The synthesis and characterization of new triphenylethylene platinum(II) complexes. Inorg Chim Acta 262:139–145
Bloemink MJ, Dorenbos JP, Heetebrij RJ, Keppler BK, Reedijk J, Zahn H (1994) New antitumor platinum compounds linked to amino phosphonic acids which lose the phosphonate and tertiary amine ligand upon binding to nucleic acids. Inorg Chem 33:1127–1132
Bloemink MJ, Diederen JJH, Dorenbos JP, Heetebrij RJ, Keppler BK, Reedijk J (1999) Calcium ions do accelerate the DNA binding of new antitumor-active platinum aminophosphonate complexes. Eur J Inorg Chem 1999:1655–1657
Blommaert FA, Michael C, Terheggen PMAB, Muggia FM, Kortes V, Schornagel JH, Hart AAM, den Engelse L (1993) Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 53:5669–5675
Blommaert FA, van Dijk-Knijnenburg HCM, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Shepman AMJ (1995) Formation of DNA adducts by the drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34:8474–8480
Boccarelli A, Coluccia M, Intini FP, Natile G, Locker D, Leng M (1999) Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands. Anti-Cancer Drug Des 14: 253–264
Bonetti A, Franceschi T, Apostoli P, Messori A, Sperotto L, Cetto GL, Molino A, Leone R (1995) Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors. Ther Drug Monit 17:25–32
Bonomi P, Modiano M, Cornett P, Koehler M, Schiller J (2001) Phase II trial to assess the activity of ZD0473 in patients with small-cell lung cancer who have failed one prior platinum-based chemotherapy regimen. Proc Am Soc Clin Oncol 20:abstract no. 1284
Boudný, V, Vrána O, Gaucheron F, Kleinwachter V, Leng M, Brabec V (1992) Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucl Acids Res 20:267–272
Brabec V, Vrana O, Kleinwachter V (1986) Tetravalent platinum complexes can exert their antitumor effect via direct reaction with DNA. Stud Biophys 114:199–207
Brabec V, Vrána O, Novákov. O, Kleinwächter V, Intini FP, Coluccia M, Natile G (1996) DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2]. Nucleic Acids Res 24:336–341
Brabec V, Kaspárkov. J, Vrána O, Novákov. O, Cox JW, Qu Y, Farrell N (1999) DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 38: 6781–6790
Brabec V, Neplechova K, Kasparkova J, Farrell N (2000) Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups. J Biol Inorg Chem 5:364–368
Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G, Gullans SR (1990) Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am J Physiol 258:F1181–1187
Britten RA, Green JA, Warenius HM (1992) Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24: 527–531
Burchenal JH, Kalaher K, O’Toole T, Chisholm J (1977) Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res 37:3455–3457
Burger AM, Double JA, Newell DR (1997) Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33:638–644
Burger H, Nooter K, Boersma AWM, Kortland CJ, Stoter G (1997) Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 73:592–599
Burger H, Nooter K, Boersma AWM, Kortland CJ, Stoter G (1998) Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 77:1562–1567
Burger H, Nooter K, Boersma AWM, Van Wingerden KE, Looijenga LHJ, Jochemsen AG, Stoter G (1999) Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 81:620628
Calvert H, Sessa C, Carmichael J, Calvert P, Zucchetti M, Marsoni S, Van den Bosch S, Robinson A, Verdi E, Camboni G (2000) An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex. Ann Oncol 11, Suppl 4:132
Calvo E, Cortes J, Rodriguez J, Rebollo J, Martin-Algarra S, Garcia-Foncillas J, Salgado E, Gonzalez-Cao M, Aramendia JM, Fernandez-Hidalgo O, Brugarolas A (2001) Irinotecan, oxaliplatin plus 5-FU/leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol 20: abstract no. 542
Chaganti RSK, Houldsworth J (2000) Genetics and biology of adult human germ cell tumors. Cancer Res 60: 1475–1482
Chen Y, Guo Z, Parsons S, Sadler PJ (1998) Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complex. Chem Eur J 4:672–676
Chen Y, Parkinson JA, Guo Z, Brown T, Sadler PJ (1999) A new platinum anticancer drug forms a highly stereoselective adduct with duplex DNA. Angew Chem Int Ed 38:2060–2063
Choi S, Filotto C, Bisanzo M, Delaney S, Lagasee D, Whitworth JL, Jusko A, Li C, Wood NA, Willingham J, Schwenker A, Spaulding K (1998) Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 37: 2500–2504
Chollet P, Bensmaïne MA, Brienza S, Deloche C, Curé H, Caillet H, Cvikovic E (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065–1070
Chresta CM, Masters JRW, Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56:1834–1841
Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ (1985) In vivo effects of cis-and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA protein cross-linking, and inhibition of replication. Biochemistry 24:7533–7540
Cleare MJ, Hoeschele JD (1973a) Antitumor platinum compounds. Relation between structure and activity. Plat Met Rev 17:2–13
Cleare MJ, Hoeschele JD (1973b) Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum(II) complexes. Bioinorg Chem 2:187–210
Coluccia M, Nassi A, Loseto F, Boccarelli A, Mariggio MA, Giordano D, Intini FP, Caputo P, Natile G (1993) A trans-platinum complex showing higher antitumor activity than the cis congeners. J Med Chem 36:510–512
Coluccia M, Boccarelli A, Mariggio MA, Cardellicchio N, Caputo P, Intini FP, Natile G (1995) Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Chem-Biol Interact 98:251–266
Coluccia M, Nassi A, Boccarelli A, Giordano D, Cardellicchio N, Locker D, Leng M, Sivo M, Intini FP, Natile G (1999a) In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands. J Inorg Biochem 77: 31–35
Coluccia M, Nassi A, Boccarelli A, Giordano D, Cardellicchio N, Intini FP, Natile G, Barletta A, Paradiso A (1999b) In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2{E-HN=C(OMe)Me}2]. Int J Oncol 15:1039–1044
Comess KM, Burstyn JN, Essigmann JM, Lippard SJ (1992) Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry 31: 3975–3990
Connors TA, Jones M, Ross WCJ, Braddock PD, Khokhar AR, Tobel ML (1972) New platinum complexes with antitumour activity. Chem-Biol Interact 5:415–424
Corda Y, Job C, Anin MF, Leng M, Job D (1993) Spectrum of DNA-platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases. Biochemistry 32:8582–8588
Cosaert J, Douillard JY, Barbarot V (2001) ZD0473 phase I trial in combination with vinorelbine in patients with refractory solid malignancies. Proc Am Soc Clin Oncol 20: abstract no. 2114
Cox JW, Berners-Price SJ, Davies MS, Qu Y, Farrell N (2001) Kinetic analysis of the stepwise formation of a long-range DNA interstrand cross-link by a dinuclear platinum antitumor complex: evidence for aquated intermediates and formation of both kinetically and thermodynamically controlled conformers. J Am Chem Soc 123:1316–1326
Cullinane C, Mazur SJ, Essigmann JM, Phillips DR, Bohr VA (1999) Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 38:6204–6212
Cure H, Forestier D, Chevalier V, Berger V, Bons JM, Mouret-Reynier MA, Chipponi J, Chollet P, Pezet D (2001) Phase II trial of chronomodulated (CM) quadritherapy combining 5-fluorouracil (5-FU), L-folinic acid (L-FA), oxaliplatin (L-OHP) and irinotecan (CPT-11) in previously untreated patients with metastatic colorectal cancer (MCC). Proc Am Assoc Cancer Res 42:620
Cvitkovic E (1998) Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24:265–281
Cvitkovic E, Bekradda M (1999) Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26: 647–662
Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703–708
Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (2000) Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne’s syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 60:1611–1619
Daoud SS, Clements MK, Small CL (1995) Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells. Anti-Cancer Drugs 6:405–412
Dedon PC, Borch RF (1987) Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955–1964
DeMario MD, Vogelzang NJ, Janisch L, Tonda M, Amantea MA, Pendyala L, Ratain MJ (1998) A phase I study of liposome-formulated cisplatin (SPI-77 R) given every 3 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 17:abstract no. 883
DeMario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, Melton K, Johnson S, Benner S, Lebwohl D (1999) A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 43:385–388
Dieras V, Bougnoux P, Petit T, Chollet P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Flesch M, Fandi R, Bensmaïne MA, Beuzeboc P (1998) Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): preliminary results. Proc Am Soc Clin Oncol 17:abstract no. 1405
Dijt FJ, Fichtinger-Shepman AMJ, Berends F, Reedijk J (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48:6058–6062
Drees M, Dengler WM, Hendriks HR, Kelland LR, Fiebig HH (1995) Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Eur J Cancer 31A:356–361
Duckett DR, Drummond JT, Murchie AIH, Reardon JT, Sancar A, Lilley DMJ, Modrich P (1996) Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A 93:6443–6447
Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161–183
Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, Searle F (2001) Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J Controlled Release 74: 135–146
Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert B (ed) Cisplatin. Chemistry and biochemistry of a leading anticancer drug. Verlag Helvetica Chimica Acta, Zürich; Wiley-VCH, Weinheim pp 111–134
Eastman A, Barry MA (1987) Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 26:3303–3307
Eastman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloro-platinum(II). Biochemistry 27:4730–4734
Ellis LT, Er HM, Hambley TW (1995) The influence of the axial ligands of a series of platinum(IV) anticancer complexes on their reduction to platinum(II) and reaction with DNA. Austr J Chem 48:793–806
Evagorou EG, Duncan R, Buckley RG, Gianasi E (1998) Polymer-platinum compounds. Pat. No. WO9847537
Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303
Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25, Suppl 5:1322
Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117–123
Farrell N (1996) Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Met Ions Biol Syst 32:603–639
Farrell N (2000) Polynuclear charged platinum compounds as a new class of anticancer agents. Toward a new paradigm. In: Kelland LR, Farrell N (eds) Platinum-based drugs in cancer therapy. Humana, Totowa, pp 321–338
Farrell NP, de Almeida SG, Skov KA (1988) Bis(platinum) complexes containing two cis-diammine units. Synthesis and initial DNA-binding studies. J Am Chem Soc 110:5018–5019
Farrell N, Ha TTB, Souchard JP, Wimmer FL, Cros S, Johnson NP (1989) Cytostatic trans-platinum(II) complexes. J Med Chem 32:2240–2241
Farrell N, Qu Y, Feng L, Van Houten B (1990) Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry 29:9522–9531
Farrell N, Kelland LR, Roberts JD, Van Beusichem M (1992) Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52:5065–5072
Farrell N, Appleton TG, Qu Y, Roberts JD, Soares Fontes AP, Skov KA, Wu P, Zou Y (1995) Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. Biochemistry 34:15480–15486
Farrell N, Qu Y, Bierbach U, Valsecchi M, Menta E (1999) Structure-activity relationships within di-and trinuclear platinum phase-I clinical anticancer agents. In: Lippert B (ed) Cisplatin. Chemistry and biochemistry of a leading anticancer drug. Verlag Helvetica Chimica Acta, Zürich; Wiley-VCH, Weinheim, pp 479–496
Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ, Lohman PHM, Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707–713
Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F (1987) cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 47:3000–3004
Fichtinger-Schepman AMJ, van der Velde-Visser SD, van Dijk-Knijnenburg HCM, van Oosterom AT, Baan RA, Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumour tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 50:7887–7894
Fiebig HH, Mross K, Henß H, Aulenbacher P, Queißer W (1991) Phase I study of the new platinum complex D 19466 on a single intermittent schedule. Eur J Cancer 27, Suppl 2:S197
Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881–4886
Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB (1998) Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77: 741–746
Fischel JL, Etienne MC, Formento P, Milano G (1998) Search for the optimal schedule for the oxaliplatin/5-fluoruracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4: 2529–2535
Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G (2001) Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 84:579–585
Fokkema E, Lunenberg J, van Putten JWG, van Rijswijk REN, Weil C, Groen HJM (1998) Randomized phase II study of oral JM216 versus intravenous (iv) cisplatin in non-small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 17:abstract no. 1858
Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C, Smith IE (1999) Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17:3822–3827
Fraval HNA, Rawlings CJ, Roberts JJ (1978) Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymidine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res 51:121–132
Frey U, Ranford JD, Sadler PJ (1993) Ring-opening reactions of the anticancer drug carboplatin: NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5′-GMP-N7)] in solution. Inorg Chem 32:1333–1340
Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393–396
Galanski MS, Keppler BK (2000) Is reduction required for antitumour activity of platinum(IV) compounds? Characterisation of a platinum(IV)-nucleotide adduct [enPt(OCOCH3)3(5′-GMP)] by NMR spectroscopy and ESI-MS. Inorg Chim Acta 300–302:783–789
Galanski MS, Slaby S, Keppler BK (1999) The mode of action of antitumor platinum compounds linked to amino phosphonic acids with particular activity against bone malignancies and the influence of calcium ions onto the DNA binding behavior. Contrib Oncol 54:435–438
Gamelin E, Allain P, Maillart P, Turcant A, Delva R, Lortholary A, Larra F (1995) Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 37:97–102
Gamelin E, Le Brouil A, Boisdron-Celle M, Turcant A, Delva R, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Robert J, Larra F, Allain P (1997) Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 3:891–899
Garufi C, Nisticö C, Brienza S, Vaccaro A, D’Ottavio A, Zappala AR, Aschelter AM, Terzoli E (2000) Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 12: 179–182
Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171–1176
Gatzemeier U, Anthoney DA, Groth G, Kaye SB, Cosaert J (2001) A phase I dose-escalation study of ZD0473 combined with paclitaxel in refractory solid malignancies. Proc Am Soc Clin Oncol 20:abstract no. 2775
Gelasco A, Lippard SJ (1999) Anticancer activity of cisplatin and related complexes. Top Biol Inorg Chem 1: 1–43
Germann N, Brienza S, Rotarski M, Emile FJ, Di Palma M, Musset M, Reynes M, Soulie P, Cvitkovic E, Misset JL (1999) Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin’s lymphoma patients. Ann Oncol 10:351–354
Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R (1999) HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 35: 994–1002
Gibbons GR, Page JD, Mauldin SK, Husain I, Chaney SG (1990) Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res 50:6497–6501
Gibbons GR, Kaufmann WK, Chaney SG (1991) Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis 12:2253–2257
Gietema JA, De Vries EGE, Sleijfer DT, Willemse PHB, Guchelaar HJ, Uges DRA, Aulenbacher P, Voegeli R, Mulder NH (1993a) A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 67:396–401
Gietema JA, Guchelaar HJ, de Vries EGE, Aulenbacher P, Sleijfer DT, Mulder NH (1993b) A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anti-Cancer Drugs 4:51–55
Gietema JA, Veldhuis GJ, Guchelaar HJ, Willemse PHB, Uges DRA, Cats A, Boonstra H, van der Graaf WTA, Sleijfer DT, de Vries EGE, Mulder NH (1995) Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 71:1302–1307
Gill I, Muggia FM, Terheggen PM, Michael C, Parker RJ, Kortes V, Grunberg S, Christian MC, Reed E, den Engelse L (1991) Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum-DNA adducts. Ann Oncol 2:115–121
Giurgiovich AJ, Diwan BA, Olivero OA, Anderson LM, Rice JM, Poirier MC (1997a) Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. Carcinogenesis 18:93–96
Giurgiovich AJ, Anderson LM, Jones AB, Dove LF, Moskal DJ, Rice JM, Olivero OA, Poirier MC (1997b) Transplacental cisplatin exposure induces persistent fetal mitochondrial and genomic DNA damage in patas monkeys. Reprod Toxicol 11:95–100
Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422
Goddard PM, Orr RM, Valenti MR, Barnard CFJ, Murrer BA, Kelland LR, Harrap KR (1996) Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. Anticancer Res 16:33–38
Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 89:3070–3074
Goldwasser F, Bozec L, Zeghari-Squalli N, Misset JL (1999) Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anti-Cancer Drugs 10:195–201
Gorbunova VA, Smirnova NB, Orel NE (1995) Phase II study of cycloplatam in advanced ovarian carcinoma. Proc Int Congress on Anti-Cancer Chemother 5:382
Gordon JA, Gattone VH (1986) Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991–998
Gore M, Atkinson RJ, Dirix L, Rischin D, Beale P, Harnet P, Hacking D, Cure H, Cosaert J (2001) ZD0473 phase II monotherapy trial in second-line ovarian cancer. Proc Am Soc Clin Oncol 20:abstract no. 2501
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–1218
Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293–2297
Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV (1980) Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 5:21–26
Gullotti M, Pasini A, Ugo R, Filippeschi S, Marmonti L, Spreafico F (1984) Enantiomeric cisplatin analogues: an investigation on their activity towards tumors in mice. Inorg Chim Acta 91:223–227
Gust R, Schönenberger H (1993) Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes. Eur J Med Chem 28:103–115
Gust R, Karl J, Faderl M, Schönenberger H (1995) Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) by variation of ring substituents. Arch Pharm 328:457–463
Gust R, Faderl M, Schönenberger H (2000) [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring 3. Investigation of breast cancer inhibiting properties. J Cancer Res Clin Oncol 126:647–654
Han I, Ling YH, Al-Baker S, Khokhar AR, Perez-Soler R (1993) Cellular pharmacology of liposomal cisbis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res 53: 4913–4919
Han I, Nguyen T, Yang LY, Khokhar AR, Perez-Soler R (1994) Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in LoVo and LoVo/PDD cells. Anti-Cancer Drugs 5:64–68
Harstrick A, Bokemeyer C, Scharnofske M, Hapke G, Reile D, Schmoll HJ (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and-resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol 33:43–47
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381
He Y, Groleau S, Gaudreault RC, Caron M, Thérien HM, Bérubé G (1995) Synthesis and in vitro biological evaluation of new triphenylethylene platinum(II) complexes. Bioorg Med Chem Lett 5:2217–2222
Hegmans A, Qu Y, Kelland LR, Roberts JD, Farrell N (2001) Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates. Inorg Chem 40:6108–6114
Heiger-Bernays WJ, Essigmann JM, Lippard SJ (1990) Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29:8461–8466
Highley MS, Calvert AH (2000) Clinical experience with cisplatin and carboplatin. In: Kelland LR, Farrell N (eds) Platinum-based drugs in cancer therapy. Humana, Totowa, pp 171–194
Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AM, Shellard SA (1994) Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30A:832–837
Hoffman P, Mauer A, Haraf D, Masters G, Lebwohl D, Krauss S, Golomb H, Vokes E (1998) Oral JM-216 plus concomitant radiotherapy for patients with advanced malignancies of the chest. Proc Am Soc Clin Oncol 17: abstract no. 1878
Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, Kelland LR (1998a) Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anti-Cancer Drug Des 13:118
Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR (1998b) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77:366–373
Hongo A, Seki S, Akiyama K, Kudo T (1994) A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Int J Biochem 26:1009–1016
Hoshi A, Castañer J (1997) TRK-710. Drugs Future 22:38–39
Hoshino T, Misaki M, Yamamoto M, Shimizu H, Ogawa Y, Toguchi H (1995) In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. J Pharm Sci 84:216–221
Houldsworth J, Xiao H, Murty VVVS, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RSK (1998) Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16:2345–2349
Inagaki K, Kidani Y (1986) Differences in binding of (1,2-cyclohexanediamine)platinum(II) isomers with d(GpG). Inorg Chem 25:1–3
Inagaki K, Nakahara H, Alink M, Kidani Y (1990) Characterization of (1,2-cyclohexanediamine)platinum(II) isomers and their d(GpG) adducts by means of proton NMR spectroscopy. A minor structural change induced by the isomers. Inorg Chem 29:4496–4500
Ishibashi T, Lippard SJ (1998) Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 95: 4219–4223
Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467–2498
Janáky T, Juhász A, Rékási Z, Serfözö P, Pinski J, Bokser L, Srkalovic G, Milanovic S, Redding TW, Halmos G, Nagy A, Schally AV (1992) Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties. Proc Natl Acad Sci U S A 89:10203–10207
Jennerwein M, Andrews PA (1994) Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett 81:215–220
Jennerwein MM, Eastman A, Khokhar A (1989) Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem-Biol Interact 70:39–49
Jennerwein MM, Eastman A, Khokhar AR (1991) The role of DNA-repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. Mutat Res 254:89–96
Johnson NP, Hoeschele JD, Rahn RO, O’Neill JP, Hsie AW (1980) Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroammines in Chinese hamster ovary cells. Cancer Res 40:1463–1468
Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC (1994a) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689–697
Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC (1994b) Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells. Cancer Res 54:5911–5916
Jones JC, Zhen W, Reed E, Parker RJ, Sancar A, Bohr VA (1991) Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266:7101–7107
Jones SF, Greco FA, Hainsworth JD, Burris HA, Calvert SA, Bulanhagui C, Lebwohl DE (1999) Phase I study of JM-216 in combination with paclitaxel in patients with advanced malignancies. Proc Am Soc Clin Oncol 18:abstract no. 831
Judson IR, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, Hanauske A (1997) Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 8:604–606
Kalinowski DP, Illenye S, Van Houten B (1992) Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction. Nucl Acids Res 20:3485–3494
Karl J, Gust R, Spruss T, Schneider MR, Schönenberger H, Engel J, Wrobel KH, Lux F, Trebert Haeberlin S (1988) Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma. J Med Chem 31:72–83
Kavanagh JJ, Edward CL, Freedman RS, Finnegan MB, Balat O, Tresukosol D, Burk K, Loechner S, Hord M, Franklin JL, Kudelka AP (1995) A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol Oncol 58:106–109
Kelland LR (2000) New platinum drugs. The pathway to oral therapy. In: Kelland LR, Farrell N (eds) Platinum-based drugs in cancer therapy. Humana, Totowa, pp 299–319
Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR (1992) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52:1710–1716
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993a) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581–2586
Kelland LR, Jones M, Gwynne JJ, Valenti M, Murrer BA, Barnard CFJ, Vollano JF, Giandomenico CM, Abrams MJ, Harrap KR (1993b) Antitumour activity of orally administered ammine/amine platinum (IV) dicarboxylate complexes against a panel of human ovarian carcinoma xenografts. Int J Oncol 2:1043–1048
Kelland LR, Barnard CFJ, Evans IG, Murrer BA, Theobald BRC, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, Rogers PM, Harrap KR (1995) Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38:3016–3024
Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813–1815
Khokhar AR, Al-Baker S, Brown T, Perez-Soler R (1991) Chemical and biological studies on a series of lipid-soluble (trans-(R,R)-and-(S,S)-1,2-diaminocyclohexane)platinum(II) complexes incorporated in liposomes. J Med Chem 34: 325–329
Khokhar AR, Al-Baker S, Shamsuddin S, Siddik ZH (1997) Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes. J Med Chem 40: 112–116
Kidani Y, Noji M, Tsukagoshi S, Tashiro T (1978a) Antitumor activity of water-soluble platinum(II) complexes of 1,2-cyclohexanediamine isomers. Gann 69:263–265
Kidani Y, Inagaki K, Iigo M, Hishi A, Kuretani K (1978b) Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 21:1315–1318
Kidani Y, Noji M, Tashiro T (1980) Antitumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers. Gann 71:637–643
Kido Y, Khokhar AR, Siddik ZH (1993a) Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anti-Cancer Drugs 4:251–258
Kido Y, Khokhar AR, Al-Baker S, Siddik ZH (1993b) Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum(IV) complexes mediated by axial and equatorial ligands. Cancer Res 53: 4567–4572
Kim DK, Ahn JS, Ryu G, Kim KH, Park CW, Kim MS, Chung MH, Shin SG, Suh YH, Kim YS (1994) General pharmacology of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II). Arzneimittelforsch/Drug Res 44:1080–1088
Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS (1995) Antitumor activity of cismalonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacol 35:441–445
Kim NK, Im SA, Kim DW, Lee MH, Jung CW, Cho EK, Lee JT, Ahn JS, Heo DS, Bang YJ (1999) Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcimona. Cancer 86:1109–1115
Kim NK, Bang Y, Heo DS, Kang Y, Kang WK, Kim H, Kim H, Kim JS, Kim HT, Roh JK (2000) SKI2053R and 5-fluorouracil (5-FU) in advanced gastric adenocarcinoma: phase II clinical trial. Proc Am Soc Clin Oncol 19: abstract no. 1277
Kim NK, Kim TY, Shin SG, Park YI, Lee JA, Cho YB, Kim KH, Kim DK, Heo DS, Bang YJ (2001) A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. Cancer 91:1549–1556
Klenner T, Wingen F, Keppler BK, Krempien B, Schmähl D (1990a) Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol 116:341–350
Klenner T, Valenzuela-Paz P, Keppler BK, Angres G, Scherf HR, Wingen F, Amelung F, Schmähl D (1990b) Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. Cancer Treat Rev 17:253–259
Klenner T, Valenzuela-Paz P, Amelung F, Münch H, Zahn H, Keppler BK, Blum H (1993) Platinum phosphonato complexes with particular activity against bone malignancies. An evaluation of an experimental tumor model highly predictive for the clinical situation. In: Keppler BK (ed) Metal complexes in cancer chemotherapy. VCH, Weinheim, pp 85–127
Knebel NG, Angerer EV (1991) 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. J Med Chem 34:2145–2152
Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972–1979
Köberle B, Payne J, Grimaldi KA, Hartley JA, Masters JRW (1996) DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 52:1729–1734
Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JRW (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70:551–555
Köberle B, Masters JRW, Hartley JA, Wood RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9:273–276
Kollmannsberger C, Rick O, Beyer J, Derigs G, Mayer F, Schleucher N, Schoeffski P, Sosada M, Spott C, Kanz L, Bokemeyer C (2001) Oxaliplatin in patients (pts) with cisplatin-refractory germ-cell cancer (GCT). Proc Am Soc Clin Oncol 20:abstract no. 770
Kozelka J, Legendre F, Reeder F, Chottard JC (1999) Kinetic aspects of interactions between DNA and platinum complexes. Coord Chem Rev 190–192:61–82
Kraker AJ, Moore CW (1988) Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 48:9–13
Küng A, Zenker A, Galanski A, Keppler BK (2001a) Capillary electrophoretic study of carboplatin and analogues with nucleoside monophosphates, di-and trinucleotides. J Inorg Biochem 83:181–186
Küng A, Strickmann DB, Galanski MS, Keppler BK (2001b) Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5′-GMP in the presence of sulfur containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. J Inorg Biochem 86:691–698
Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC (1988) Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 37:4597–4600
Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522–1534
LeDoux SP, Wilson GL, Beecham EJ, Stevnsner T, Wassermann K, Bohr VA (1992) Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis 13:1967–1973
Legendre F, Bas V, Kozelka J, Chottard JC (2000) A complete kinetic study of GG versus AG platination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species. Chem Eur J 6:2002–2010
Levi F, Metzger G, Massari C, Milano G (2000) Oxaliplatin. Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1–21
Luo FR, Wyrick SD, Chaney SG (1998) Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res 10:595–603
Luo FR, Yen TY, Wyrick SD, Chaney SG (1999a) High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B, 724:345–356
Luo FR, Wyrick SD, Chaney SG (1999b) Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol 13:159–169
Luo FR, Wyrick SD, Chaney SG (1999c) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19–28
Luo FR, Wyrick SD, Chaney SG (1999d) Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44:29–38
MacLean DS, Khokhar AR, Tyle P, Perez-Soler R (2000) Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) a potential antitumour agent. J Microencapsulat 17:307–322
Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 65:271–284
Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500–3505
Mani S, Manalo J, Bregman D (2000) Novel combinations with oxaliplatin. Oncology 14, Suppl 11:52–58
Manzotti C, Pratesi G, Menta E, Di Domenico R, Cavalletti E, Fiebig HH, Kelland LR, Farrell N, Polizzi D, Supino R, Pezzoni G, Zunino F (2000) BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 6:2626–2634
Masters JRW, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H (1996) Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A:1248–1253
Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48: 5713–5716
Masuda H, Tanaka T, Matsuda H, Kusaba I (1990) Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 50:1863–1866
Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL (1986) A phase I trial of trans-diaminocyclohexane oxalato-platinum(l-OHP). Biomed Pharmacother 40: 372–376
Mathé G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, de Vassals F, Chenu E, Bourut C (1989) Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43: 237–250
Matveev BP, Gorbunova VA, Smirnova NB, Zhumagazin ZD, Bukharin BV, Orel NF (1996) Cycloplatam in the treatment of patients with disseminated prostatic cancer. Urol Nefrol (Mosk) 1996:34–36
May A, Nairn RS, Okumoto DS, Wassermann K, Stevnsner T, Jones JC, Bohr VA (1993) Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J Biol Chem 268:1650–1657
McKeage MJ, Raynaud F, Ward J, Berry C, O’Dell D, Kelland LR, Murrer B, Santabŕabara P, Harrap KR, Judson IR (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691–2700
Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, De Vries EGE (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52:6885–6889
Mellish KJ, Kelland LR, Harrap KR (1993) In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68:240–250
Mellish KJ, Barnard CFJ, Murrer BA, Kelland LR (1995) DNA-binding properties of novel cis-and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 62:717–723
Mello JA, Lippard SJ, Essigmann JM (1995) DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34:14783–14791
Mello JA, Acharya S, Fishel R, Essigmann JM (1996) The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3:579–589
Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H, Matsumura T (2001) Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy 47: 136–142
Metzger SW, Keppler BK (1999) Potential in inhibition of telomerase activity and cytotoxicity of different platinum compounds. 8th Int Symp Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy: 4.P14
Meyn RE, Jenkins SF, Thompson LH (1982) Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells. Cancer Res 42:3106–3110
Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E (2000) Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35:75–93
Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, Soulié P, Armand JP, Cvitkovic E, de Cremoux H (1998) Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 34:1124–1127
Montero EI, Diaz S, González-Vadillo AM, Pérez JM, Alonso C, Navarro-Ranninger C (1999) Preparation and characterization of novel trans-[PtCl2(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem 42:4264–4268
Murata T, Hibasami H, Maekawa S, Tagawa T, Nakashima K (1990) Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int 20:949–955
Natile G, Coluccia M (1999) trans-Platinum compounds in cancer therapy: a largely unexplored strategy for identifying novel antitumor platinum drugs. Top Biol Inorg Chem 1:73–98
Natile G, Coluccia M (2001) Current status of trans-platinum compounds in cancer therapy. Coord Chem Rev 216–217:383–410
Nehmé A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JYJ, Christen RD (1999) Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and-deficient cells. Br J Cancer 79: 1104–1110
Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1–7
Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, Montgomery EA, Bischoff EK, Cullen KJ (1996) Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2:1859–1865
Noji M, Okamoto K, Kidani Y (1981) Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388. J Med Chem 24: 508–515
Novákov. O, Vrána O, Kiseleva VI, Brabec V (1995) DNA interactions of antitumor platinum(IV) complexes. Eur J Biochem 228:616–624
O’Dwyer PJ, Moyer JD, Suffness M, Harrison SD Jr, Cysyk R, Hamilton TC, Plowman J (1994) Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res 54:724–729
O’Dwyer PJ, Stevenson JP, Johnson SW (1999) Clinical status of cisplatin, carboplatin, and other platinum-based antitumor drugs. In: Lippert B (ed) Cisplatin. Chemistry and biochemistry of a leading anticancer drug. Verlag Helvetica Chimica Acta, Zürich; Wiley-VCH, Weinheim, pp 31–69
O’Dwyer PJ, Stevenson JP, Redlinger M, Sun W, Giantonio B, Hahn S, Algazy K, Burnite M, Koehler M (2001) Phase I trial of the novel platinum analogue ZD0473 in combination with gemcitabine for patients with advanced cancers. Proc Am Soc Clin Oncol 20:abstract no. 1354
Ohndorf UM, Whitehead JP, Raju NL, Lippard SJ (1997) Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry 36:14807–14815
Oldenburg J, Begg AC, van Vugt MJH, Ruevekamp M, Schornagel JH, Pinedo HM, Los G (1994) Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res 54:487–493
Olivero OA, Semino C, Kassim A, Lopez-Larraza DM, Poirier MC (1995) Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 346:221–230
Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, Poirier MC (1997) Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 391:79–86
O’Neill CF, Hunakova L, Kelland LR (1999) Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and-resistant human ovarian carcinoma cells. Chem-Biol Interact 123:11–29
O’Rourke TJ, Weiss GR, New P, Burris HA, Rodriguez G, Eckhart J, Hardy J, Kuhn JG, Fields S, Clark GM, Von Hoff DD (1994) Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anti-Cancer Drugs 5: 520–526
Ota K, Miyake H, Inuyama I et al. (1991) Clinical evaluation of cis-diammine (glycolato) plat 254-S, a new anticancer platinum complex. Proc NCI-EORTC Symp New Drugs in Cancer Therapy 7:340
Page JD, Husain I, Sancar A, Chaney SG (1990) Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29:1016–1024
Parker RJ, Eastman A, Bostick-Bruton F, Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772–777
Peereboom DM, Wood L, Connell C, Spisak J, Smith D, Liebwohl D, Bukowski RM (1997) Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 16:abstract no. 1210
Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970–5976
Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177–184
Pera MF, Friedlos F, Mills J, Roberts JJ (1987) Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res 47:6810–6813
Perego P, Zunino F, Carenini N, Giuliani F, Spinelli S, Howell SB (1998) Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Mol Pharmacol 54:213–219
Perego P, Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano I, Leone R, Spinelli S, Pezzoni G, Manzotti C, Farrell N, Zunino F (1999a) A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 55:528–534
Perego P, Gatti L, Caserini C, Supino R, Colangelo D, Leone R, Spinelli S, Farrell N, Zunino F (1999b) The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J Bioinorg Chem 77:59–64
Pérez JM, Montero EI, González AM, Alvarez-Valdés A, Alonso C, Navarro-Ranninger C (1999) Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2(isopropylamine)(amine’)] complexes. J Inorg Biochem 77:37–42
Perez-Soler R, Khokhar AR (1992) Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res 52:6341–6347
Perez-Soler R, Khokhar AR, Lopez-Berestein G (1987) Treatment of prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) encapsulated in multilamellar vesicles. Cancer Res 47:6462–6466
Perez-Soler R, Yang LY, Drewinko B, Lauterzstain J, Khokhar AR (1988) Increased cytotoxicity and reversal of resistance to cis-diamminedichloroplatinum(II) with entrapment of cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexaneplatinum(II) in multilamellar lipid vesicles. Cancer Res 48:4509–4512
Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Micias-Kiger D, Raber MN, Khokhar AR (1990) Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(II). Cancer Res 50:4254–4259
Perez-Soler R, Siddik ZH, Chase J, Al-Baker S, Khikhar AR, Pazdur R (1993) Phase I clinical and pharmacology study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (l-NDDP). Proc Am Soc Clin Oncol 12:153
Perez-Soler R, Han I, Al-Baker S, Khokhar AR (1994) Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups. Cancer Chemother Pharmacol 33:378–384
Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee JS, Khokhar AR, Hong WK (1997) Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 3:373–379
Perez-Soler R, Walsh GL, Swisher SG, Shin HJC, Kemp BL, Terry K, Khuri FR, Fossella FV, Hong WK, Lopez-Berestein G, Khokhar AR, Shin DM (1999) Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered in patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 18:abstract no. 1626
Petersen LN, Mamenta EL, Stevsner T, Chaney SG, Bohr VA (1996) Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis 17:2597–2602
Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, Van Glabekke M, Lacombe D, Pinel MC, Pecorelli S (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18:1193–1202
Pil PM, Lippard SJ (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256:234–237
Plooy ACM, van Dijk M, Berends F, Lohman PHM (1985) Formation and repair of DNA interstrand crosslinks in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res 45:4178–4184
Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F (1999) A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 80: 1912–1919
Presnov MA, Konovalova AL (1988) Cycloplatam and oxoplatin the new antitumor platinum compounds of the second generation. Arch Geschwulstforsch 58:43–49
Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluoruracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 8:876–885
Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD (1998) Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 4:1021–1029
Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CFJ, Murrer BA, Harrap KR (1996) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155–162
Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR (1997) cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 3:2063–2074
Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968–3971
Redon S, Bombard S, Elizondo-Riojas MA, Chottard JC (2001) Platination of the (T2G4)4 telomeric sequence: a structural and cross-linking study. Biochemistry 40:8463–8470
Reedijk J (1999) Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 99:2499–2510
Riccardi A, Meco D, Ferlini C, Servidei T, Carelli G, Segni G, Manzotti C, Riccardi R (2001) In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother Pharmacol 47:498–504
Richards EH, Hickey E, Weber L, Masters JRW (1996) Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56:2446–2451
Richon VM, Schulte N, Eastman A (1987) Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 47:2056–2061
Ridgway H, Hall LM, Speer RJ, Stewart DP, Edwards GR, Hill JM (1976) Antitumor activity of cis-dichloro-(1,2-diaminocyclohexane)platinum(II). J Clin Hematol Oncol 6:11–16
Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s anticancer drug screen panel. Biochem Pharmacol 52:1855–1865
Roat RM, Reedijk J (1993) Reaction of mer-trichloro(diethylenetriamine)platinum(IV) chloride, (mer-[Pt(dien)Cl3]Cl), with purine nucleosides and nucleotides results in formation of platinum(II) as well as platinum(IV) complexes. J Inorg Biochem 52:263–274
Roberts JD, Van Houten B, Qu Y, Farrell NP (1989) Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Res 17:9719–9733
Roberts JD, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N (1999) Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem 77: 47–50
Roberts JJ, Fraval HNA (1978) The interaction of antitumor platinum compounds with cellular DNA in cultured cells and animal tissues: relationship to DNA cellular repair processes. Biochimie 60:869–877
Roberts JJ, Friedlos F (1987) Differential toxicity of cis-and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts. Cancer Res 47: 31–36
Rogers PM, Boxall F, Allott CP, Stephens T, Kelland LR (2000) In vitro combination studies with the sterically hindered platinum drug, ZD0473, in cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Proc 11th NCI EORTC AACR Symp, abstract no. 352
Rose WC (1997) Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 40:51–56
Rosenberg B (1978) Platinum complexes for the treatment of cancer. Interdiscip Sci Rev 3:134–147
Rosenberg B, Van Camp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386
Sargent JM, Elgie AW, Williamson CJ, Taylor CG (1996) Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Br J Cancer 74:1730–1733
Saris CP, van der Vaart PJ, Rietbroek RC, Blommaert FA (1996) In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17: 2763–2769
Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijo N (1989) Pharmacokinetics of (glycolato-O,O′)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246
Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N (1991) Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continous intravenous infusion. Cancer Res 51:1472–1477
Schellens JHM, Groenewegen G, Meerum Terwogt JM, Maliepaard M, Tibben MM, Pluim D, ten Bokkel Huinink WW, Scot M, Welbank H, Blijham GH, Beijnen JH (1999) Phase I and pharmacologic study of Stealth-liposomal encapsulated cisplatin (SPI-077). Proc Am Soc Clin Oncol 18:abstract no. 774
Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, Young RC, Ozols RF, O’Dwyer PJ (1994) Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54:709–717
Schlemmer R, Spruß T, Bernhardt G, Schönenberger H (1999) [meso-1,2-Bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers—evidence for a diethylstilbestrol-like mode of action. Arch Pharm Med Chem 332:59–69
Schmidt W, Chaney SG (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799–805
Schmoll HJ, Kohne CH, Papageorgiou E, Luft S, Harstrick A, Bachmann P, Hilgard P, Schubert U (1995) Single agent lobaplatin is active in patients with esophageal squamous cell carcinoma: a phase II evaluation. Proc Am Soc Clin Oncol 14:abstract no. 483
Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ (1997) Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 76: 502–510
Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82:966–972
Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R (2001) The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 37: 930–938
Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Viganò L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S (2000) Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol 11:977–983
Sharp SY, Rogers PM, Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1:981–989
Siddik ZH, Al-Baker S, Burditt TL, Khokhar AR (1993) Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes. J Cancer Res Clin Oncol 120:12–16
Siddik ZH, Al-Baker S, Thai G, Khokhar AR (1994a) Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes. J Cancer Res Clin Oncol 120:409–414
Siddik ZH, Al-Baker S, Thai G, Khokhar AR (1994b) Modulatory effects of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. Anti-Cancer Drug Des 9: 139–151
Simmonds AP, McDonald EC (1984) Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay. Br J Cancer 50:317–326
Skou G, Mangold G, Dexter D, Von Hoff D (1996) Comparison of an oxaliplatin-taxol versus a carboplatin-taxol regimens in the treatment of the MV-522 human lung tumor xenograft. Proc Am Ass Cancer Res 37:375
Slaby S, Galanski MS, Metzger SW, Keppler BK (1999) Design of platinum complexes with high affinity for osteosarcoma and bone metastases—structure-activity relationship. Contrib Oncol 54:201–205
Sorenson CM, Eastman A (1988a) Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48:4484–4488
Sorenson CM, Eastman A (1988b) Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48:6703–6707
Sorenson CM, Barry MA, Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82:749–755
Stevenson JP, Blair IA, Redlinger M, Sun W, Oe T, Koehler M, Roberts DW, Malone MD, O’Dwyer PJ (2001) Pharmacokinetic/pharmacodynamic trial of the novel platinum compound ZD0473 administered as an iv infusion every 21 days. Proc Am Soc Clin Oncol 20:abstract no. 450
Stewart DR, Shannon KF, Callahan EH, Jacob JE, Juthy CL, Buckley RG, Duncan R (1999) Optimization of the synthesis and purification of a polymer-based carboplatin analog. 8th Int Symp Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy:1.09
Takigawa N, Segawa Y, Ueoka H, Kiura K, Tabata M, Shibayama T, Takata I, Miyamoto H, Eguchi K, Harada M (2000) Combination of nedaplatin and vindesine for treatment of relapsed or refractory nonsmall-cell lung cancer. Cancer Chemother Pharmacol 46:272–278
Talman EG, Brüning W, Reedijk J, Spek AL, Veldman N (1997) Crystal and molecular structures of asymmetric cis-and trans-platinum(II/IV) compounds and their reactions with DNA fragments. Inorg Chem 36:854–861
Teuben JM, Reedijk J (2000) Reaction of DNA oligonucleotides with [Pt(dien)GSMe]2+ (GSMe = S-methylated glutathione) and cis-[Pt(NH3)2(GSMe)2]2+: evidence of oligonucleotide platination via sulfur-coordinated platinum intermediates. J Biol Inorg Chem 5:463–468
Teuben JM, Rodriguez I, Zubiri M, Reedijk J (2000) Glutathione readily replaces the thioether on platinum in the reaction with [Pt(dien)(GSMe)]2+ (GSMe = S-methylated glutathione); a model study for cisplatin-protein interactions. J Chem Soc Dalton Trans 2000:369–372
Trask C, Silverstone A, Ash CM, Earl H, Irwin C, Bakker A, Tobias JS, Souhami RL (1991) A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J Clin Oncol 9:1131–1137
Treat J, Huang C, Damjanou N, Jahanzeb M, Edelman M, Cosaert J, Koehler M (2001) Phase II monotherapy trial of ZD0473 as second-line therapy in non-small cell lung cancer. Proc Am Soc Clin Oncol 20:abstract no. 2808
Trigo JM, Beale P, Judson IR, Raynaud F, Rees C, Milan D, Wolf L, Walker R, Hanwell J, Giandomenico C (1999) Phase I and pharmacokinetic study of cis-amminedichloro(2-methylpyridine)platinum(II) (ZD0473), a novel sterically hindered platinum complex, in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 18:abstract no. 648
Trimmer EE, Zamble DB, Lippard SJ, Essigmann JM (1998) Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry 37:352–362
Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K, Yoshioka T (1998) Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer 34:1796–1801
Vadiei K, Siddik ZH, Khokhar AR, Al-Baker S, Sampedro F, Perez-Soler R (1992) Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 30:365–369
Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579–3585
Van Beusichem M, Farrell N (1992) Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization and biological activity of complexes with planar ligands pyridine, Nmethylimidazole, thiazole and quinoline. The crystal and molecular structure of trans-dichlorobis(thiazole) platinum(II). Inorg Chem 31: 634–639
Van Boom SSGE, Chen BW, Teuben JM, Reedijk J (1999) Platinumthioether bonds can be reverted by guanineN7 bonds in Pt(dien)2+ model adducts. Inorg Chem 38:1450–1455
Van der Vaart PJM, Klaren HM, Hofland I, Begg AC (1997) Oral platinum analog JM216, a radiosensitizer in oxic murine cells. Int J Radiat Biol 72:675–683
Van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242–261
Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, Yule SM, Morland B, Estlin EJ, Hale JP, Pearson ADJ, Welbank H, Boddy AV (2001) A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 84:1029–1035
Vermorken JB, van der Vijgh WJF, Klein I, Hart AAM, Gall HE, Pinedo HM (1984) Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68:505–513
Verschraegen CF, Mansfield PF, Feig BW, Steger M, Wu QP, MacLean D, Siddik Z, Perez-Soler R, Hu W, Kudelka AP, Kavanagh JJ, Khokhar AR (1999) Phase I study of an intraperitoneal liposomal cisplatin analog L-NDDP for treatment of peritoneal carcinomatosis. Proc Am Soc Clin Oncol 18:abstract no. 1405
Vichi P, Coin F, Renaud JP, Vermeulen W, Hoeijmakers JHJ, Moras D, Egly JM (1997) Cisplatin-and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J 16:7444–7456
Voegeli R, Schumacher W, Engel J, Respondek J, Hilgard P (1990) D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol 116:439–442
Vollano JF, Al-Baker S, Dabrowiak JC, Schurig JE (1987) Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J Med Chem 30:716–719
Wang K, Lu J, Li R (1996) The events that occur when cisplatin encounters cells. Coord Chem Rev 151: 53–88
Welink J, Pechstein B, van der Vijgh WJF (1996) Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. J Chromatography B 675:107–111
Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, Adams DJ, Lewis AD, Scott ARR, Smyth JF (1987) Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer 39:695–702
Wong E, Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451–2466
Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P (1998) Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770–777
Woynarowski JM, Faivre S, Herzig MCS, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE (2000) Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920–927
Yamada H, Uchida N, Maekawa R, Yoshioka T (2001) Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 172:17–25
Yang LY, Li L, McLean D, Jiang H, Khokhar AR, Perez-Soler R (1998) Inefficient cellular repair of DNA adducts induced by cis-bis-neodecanoato-trans-R,R-1,2-diamminocyclohexane platinum(II). 10th NCIEORTC Symp New Drugs in Cancer Therapy, p 137
Yoshida M, Khokhar AR, Siddik ZH (1994) Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). Cancer Res 54: 4691–4697
Yoshioka T, Gamoh M, Shineha R, Ishibashi S, Shibata H, Suzuki T, Murakawa Y, Kato S, Shimodaira H, Kato S, Ishioka C, Kanamaru R (1999) A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Internal Med 38:844–848
Zákovská A, Novákov. O, Balcarová Z, Bierbach U, Farrell N, Brabec V (1998) DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. Eur J Biochem 254:547–557
Zaludov. R, Zákovská A, Kaspárkova J, Balcarová Z, Vrána O, Coluccia M, Natile G, Brabec V (1997) DNA modifications by antitumor trans-[PtCl2(E-iminoether)2]. Mol Pharmacol 52: 354–361
Zamble DB, Lippard SJ (1999) The response of cellular proteins to cisplatin-damaged DNA. In: Lippert B (ed) Cisplatin. Chemistry and biochemistry of a leading anticancer drug. Verlag Helvetica Chimica Acta, Zürich; Wiley-VCH, Weinheim, pp 73–110
Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35:10004–10013
Zamboni WC, Gervais AC, Egorin MJ, Schellens JHM, Delauter BJ, Zuhowski EG, Pluim D, Hamburger DR, Working PK, Colbern G, Eiseman JL (2000) Disposition of platinum (Pt) in B16 murine melanoma tumours after administration of cisplatin or pegylated liposomal-cisplatin formulations (SPI-077 and SPI-077 B103). Proc 11th NCI EORTC AACR Symp: abstract no. 132
Zang DY, Lee KH, Lee JS, Lee JH, Kim WK, Kim SH, Kim WD, Kim DS, Kim JH, Kim BS, Cho YB, Kim DK, Kim KH (1999) Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. Am J Clin Oncol 22:495–498
Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F (1999) Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5: 1189–1196
Zehnulova J, Kasparkova J, Farrell N, Brabec V (2001) Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J Biol Chem 276:22191–22199
Zhang JG, Lindup WE (1993) Role of mitochondria in cisplatin-induced oxidative damage exhibited by renal cortical slices. Biochem Pharmacol 45:2215–2222
Zhang JG, Lindup WE (1994) Cisplatin nephrotoxicity: decreases in mitochondrial protein sulfhydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem Pharmacol 47:1127–1135
Zhen W, Link CJ Jr, O’Connor PM, Reed E, Parker R, Howell SB, Bohr VA (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689–3698
Zimmermann W, Galanski MS, Keppler BK (1999) New antitumor platinum-albumine conjugates for targeted drug delivery. 8th Int Symp Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy:1.08
Zou Y, Van Houten B, Farrell N (1993) Ligand effects in platinum binding to DNA. A comparison of DNA binding properties for cis-and trans-[PtCl2(amine)2] (amine = NH3, pyridine). Biochemistry 32:9632–9638
Zou Y, Van Houten B, Farrell N (1994) Sequence specificity of DNA-DNA interstrand cross-link formation by cisplatin and dinuclear platinum complexes. Biochemistry 33:5404–5410
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag
About this chapter
Cite this chapter
Jakupec, M.A., Galanski, M.S., Keppler, B.K. (2003). Tumour-inhibiting platinum complexes—state of the art and future perspectives. In: Amara, S.G., et al. Reviews of Physiology, Biochemistry and Pharmacology. Reviews of Physiology, Biochemistry and Pharmacology, vol 146. Springer, Berlin, Heidelberg. https://doi.org/10.1007/s10254-002-0001-x
Download citation
DOI: https://doi.org/10.1007/s10254-002-0001-x
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00228-4
Online ISBN: 978-3-540-36207-4
eBook Packages: Springer Book Archive